|
WASHINGTON (AP) - Drug maker Boehringer Ingelheim has told regulators that patients using its respiratory inhaler may face a greater risk of stroke.
The Food and Drug Administration said Tuesday that data submitted by the German drug maker show a slightly higher rate of stroke for patients using its Spiriva Handihaler, compared with a placebo. FDA said it has not yet analyzed the figures, which were compiled from 29 patient studies.
According to the company's analysis, two out of every 1,000 patients using Spiriva are at risk for stroke.
|